Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P50391

UPID:
NPY4R_HUMAN

ALTERNATIVE NAMES:
Pancreatic polypeptide receptor 1

ALTERNATIVE UPACC:
P50391; Q13456; Q5ISU3; Q5T2X9; Q6FH06

BACKGROUND:
The protein Neuropeptide Y receptor type 4, alternatively known as Pancreatic polypeptide receptor 1, with the unique identifier P50391, is integral to cellular communication. It acts as a G protein-coupled receptor for peptides such as PPY, NPY, and PYY, inversely affecting cAMP levels. The receptor's affinity for these peptides varies, suggesting its critical role in modulating physiological responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Neuropeptide Y receptor type 4 holds significant promise for identifying new therapeutic approaches. Its key role in mediating peptide-induced signaling pathways could be harnessed to devise innovative treatments for diseases linked to peptide dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.